Email
Mot de passe
Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

BiomimX srl

BiomimX srl_logo
9
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

BiomimX develops human beating organ-on-chips as innovative platforms to create preclinical models with real tissue functionality to test safety and benefit of drugs in a more reliable fashion.

Milano, Lombardia, Italy

Send a message

  • 2

    employees

  • €0

    turnover

Anglais

BiomimX srl

Anglais

BiomimX develops human beating organ-on-chips as innovative platforms to create preclinical models with real tissue functionality to test safety and benefit of drugs in a more reliable fashion. BiomimX addresses the urgent need of Pharma companies for advanced in vitro models of human organs and diseases, with the final aim to lead to a more efficient, faster and less expensive launch of drugs into market. This need is also driven by a paradigm shift towards the 3R principles, forcing...

See more

BiomimX develops human beating organ-on-chips as innovative platforms to create preclinical models with real tissue functionality to test safety and benefit of drugs in a more reliable fashion. BiomimX addresses the urgent need of Pharma companies for advanced in vitro models of human organs and diseases, with the final aim to lead to a more efficient, faster and less expensive launch of drugs into market. This need is also driven by a paradigm shift towards the 3R principles, forcing Pharma to reduce animal testing. Thanks to its core uBeat technology, BiomimX engineers 3D human microtissues featuring an unprecedented resemblance to native organs and disease, addressing two of the main problems faced today by Pharma companies. Drug safety: Cardiovascular toxicity is one of the leading causes of drug attrition, responsible for 45% of drugs withdrawal from the market. Reliable in vitro tools to predict cardiotoxicity in early pre-clinical phases are not yet available.  BiomimX has developed uHeart, a 3D miniaturized in vitro model of a human beating heart enabling for the first time for a real-time detection of drug-induced cardiotoxicity. Drug benefit: BiomimX also focuses in paradigmatic pathologies where treatments are absent due to a complete lack in preclinical models. Among them, Osteoarthritis (OA) has high incidence but no treatment available. BiomimX has developed uKnee, the first in vitro model of human OA cartilage. 

  • 1

    Like

Our latest news

Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not received funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1112 Entities

Communities